Dianthus Therapeutics, Inc. /DE/
Nasdaq · Healthcare · Pharmaceutical Preparations · New York, NY
DNTH chart
What traders are saying about $DNTH
Latest postsDianthus Therapeutics, Inc. /DE/ news
- Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x Run
Yahoo Finance ·
- Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion
investorshub.advfn.com ·
- Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
Yahoo Finance ·
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance ·
- Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Yahoo Finance ·
- Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
Yahoo Finance ·
- Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run
Yahoo Finance ·
- Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
Yahoo Finance ·
- UiPath downgraded, Shell upgraded: Wall Street's top analyst calls
Yahoo Finance ·
- Dianthus Therapeutics to Participate in Three Investor Conferences During September
Yahoo Finance ·
- Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Yahoo Finance ·
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Yahoo Finance ·
Dianthus Therapeutics, Inc. /DE/ key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | $6.4M |
| Net income | -$162.3M | -$85.0M | -$43.5M | -$28.5M |
| Diluted EPS | $-4.20 | $-2.55 | $-8.45 | $-32.57 |
| Total assets (year end) | $530.9M | $374.0M | $179.4M | $83.1M |
| Cash and equivalents (year end) | $51.1M | $22.8M | $132.3M | $15.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Dianthus Therapeutics, Inc. /DE/
- Ticker
- DNTH (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1690585
- Former names
- Magenta Therapeutics, Inc.
Frequently asked questions
What exchange is Dianthus Therapeutics, Inc. /DE/ listed on?
Dianthus Therapeutics, Inc. /DE/ trades on the Nasdaq under the ticker symbol DNTH.
What industry is Dianthus Therapeutics, Inc. /DE/ in?
Dianthus Therapeutics, Inc. /DE/ is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Dianthus Therapeutics, Inc. /DE/ headquartered?
Dianthus Therapeutics, Inc. /DE/'s business address on file with the SEC is in New York, NY.
When does Dianthus Therapeutics, Inc. /DE/'s fiscal year end?
Dianthus Therapeutics, Inc. /DE/'s fiscal year ends on December 31.
How much revenue did Dianthus Therapeutics, Inc. /DE/ report?
Dianthus Therapeutics, Inc. /DE/ reported $2.0M in revenue for calendar year 2025, according to its SEC filings.